Is Anti-Müllerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy?

Journal: Breast care (Basel, Switzerland)
Published Date: Mar 4, 2021

Abstract

INTRODUCTION: Anti-Müllerian hormone (AMH) is the most reliable biomarker of ovarian reserve; however, its role in predicting ovarian recovery after chemotherapy is unclear. Administration of a GnRH analog (GnRHa) during chemotherapy significantly reduces the ovarian failure rate and increases the pregnancy rate. The available data on the behavior of AMH during concurrent administration of chemotherapy and GnRHa are inconsistent. We investigated whether concurrent administration of triptorelin and adjuvant chemotherapy might reduce the expected drop of AMH.

Authors

  • Rosalba Torrisi
    IRCCS Humanitas Research Hospital Medical Oncology Unit, Rozzano, Italy.
  • Vera Basilico
    Medical Oncology Unit, Istituto Clinico Mater Domini Humanitas, Castellanza, Italy.
  • Laura Giordano
    IRCCS Humanitas Research Hospital Medical Oncology Unit, Rozzano, Italy.
  • Michele Caruso
    Medical Oncology Humanitas Centro Catanese di Oncologia, Catania, Italy.
  • Antonino Musolino
    Breast Unit, University Hospital of Parma, Parma, Italy.
  • Marta Noemi Monari
    Laboratory of Clinical Analysis, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.
  • Carlo Carnaghi
    Medical Oncology Unit, Istituto Clinico Mater Domini Humanitas, Castellanza, Italy.
  • Armando Santoro
    IRCCS Humanitas Research Hospital Medical Oncology Unit, Rozzano, Italy.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals